Myeloproliferative neoplasms trials in Germany

In Germany 27 Also abroad 210

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Where
Aachen, Cottbus, Dresden, Erlangen, Essen, Hamburg, Hanover, Jena, Mannheim, Minden
Age
18 years and over
People
460 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Aachen, Augsburg, Bad Saarow, Berlin, Bonn, Chemnitz, Dresden, Erlangen, Frankfurt Am Main, Freiburg im Breisgau, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mannheim, Marburg, Muenchen, Munich, Regensburg, Ulm, Wuerzburg
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Where
Berlin, Chemnitz, Freiburg im Breisgau, Halle (Saale), Jena, Koblenz, Minden, Mutlangen
Age
18 years and over
People
324 worldwide
Run by
Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00
Phase 3Taking people
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Where
Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg, Jena, Lübeck, Mannheim, Minden
Age
18 years and over
People
426 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
Aachen, Berlin, Essen, Hanover, Heidelberg, Regensburg
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 2Taking people
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Where
Essen, Jena, Luebeck, Mannheim, Munich
Age
18 years and over
People
68 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00
Phase 1Taking people
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Where
Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz
Age
18 years and over
People
218 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00
Phase 3Taking people
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Where
Deggendorf, Dresden, Frankfurt, Greifswald, Halle, Hamburg, Heidelberg, Jena, Mannheim, Mutlangen, Rostock
Age
18 years and over
People
250 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Halle (Saale), Luebeck
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00
Phase 2Taking people
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Where
Duesseldorf, Jena
Age
18 years and over
People
38 worldwide
Run by
Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 · EU 2024-511309-47-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Aachen, Freiburg im Breisgau, Lübeck, Mannheim
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Where
Dresden, Duesseldorf, Freiburg im Breisgau, Halle (Saale), Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Munich, Mutlangen, Nuremberg, Stuttgart, Ulm
Age
18 years and over
People
126 worldwide
Run by
Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 · EU 2023-504724-25-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Leipzig, Ulm
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseNot yet taking people in Germany
Dresden MDS Registry With an Accompanying Biomaterial Collection
Where
Dresden
Age
18 years and over
People
500
Run by
Technische Universität Dresden
See details and how to joinNCT07561385
No phaseTaking people
Exercise Training in Patients With Myeloproliferative Neoplasms
Where
Hanover
Age
18 years and over
People
80
Run by
Hannover Medical School
See details and how to joinNCT07384039
Phase 1Taking people
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Where
Dresden, Halle, Mainz
Age
18 years and over
People
120 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07008118
No phaseTaking people
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Where
Halle, Hanover, Minden
Age
18 years to 100 years
People
617 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06533813
No phaseTaking people
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Where
Halle, Hanover, Minden
Age
18 years to 100 years
People
678 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT07203768
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
No phaseTaking people
Research Platform Myelofibrosis and Anemia
Where
Multiple Locations
Age
18 years and over
People
200
Run by
iOMEDICO AG
See details and how to joinNCT06976918
No phaseTaking people
MPN Childhood Registry
Where
Erlangen
Age
0 years to 17 years
People
500
Run by
University of Erlangen-Nürnberg Medical School
See details and how to joinNCT07410247
Phase 3Taking people
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Where
Dresden
Age
18 years and over
People
220 worldwide
Run by
Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00
Phase 2Taking people
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Where
Düsseldorf, Jena
Age
18 years and over
People
58 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT05980806
No phaseTaking people
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Where
Hanover
Age
18 years and over
People
200
Run by
iOMEDICO AG
See details and how to joinNCT06743035
Phase 3Taking people
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Where
Düsseldorf, Freiburg im Breisgau, Halle, Hamburg, Hanover, Heidelberg, Jena, Kiel, Leipzig, Munich, Mutlangen, Nuremberg, Stuttgart, Ulm
Age
18 years and over
People
600 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT06479135